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| INTRODUC TI ON
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, accounting for approximately 25% of childhood malignancies. 1 Overall 5-year event-free survival (EFS) rate for this disease now exceeds 80% in developed countries; [2] [3] [4] however, 10%-20% of patients succumb to recurrences. The prognosis for relapsed ALL is dismal, even with aggressive salvage strategies. 5 Thus, relapsed ALL remains a leading cause of cancer-related deaths in children.
Current comprehensive genome sequencing of triplicate diagnostic, remission, and relapsed samples from childhood ALL suggests that most relapsed patients have new, secondary genetic alterations or acquired lesions that likely occurred in a minor clone after the original diagnosis of ALL. One of the pathways enriched in recent relapse pair samples is TP53 mutations. 6 TP53 mutations are infrequent (2%-3%) at initial diagnosis and have not been found to be an important marker for prognosis or in the prediction of treatment response in most childhood ALL clinical trials. 7, 8 However, TP53 alterations are frequently found in low-hypodiploidy ALL, with a somatic mutation rate of up to 90%. 9 The incidence of TP53 alterations is higher in relapsed childhood ALL samples than in diagnostic samples. 10, 11 Back-tracking studies showed that most TP53 genetic alterations were relapse-specific, 10 which was confirmed through whole exome sequencing. 6 Numerous prognostic markers predict disease outcomes or relapse in newly diagnosed childhood ALL, especially B-cell ALL. 1, 3, 12, 13 TP53 alterations are important genetic events, but poor prognostic markers for relapsed childhood ALL in clinical trials. 10, 11 After relapse, minimal residual disease measurements might be the only prognostic marker after reinduction of chemotherapy to predict survival after stem-cell transplantation. 14 TP53 relapse-specific mutations were observed in approximately 10% of relapsed Caucasian patients. 10, 11 However, there are currently few prognostic markers for relapsed patients that indicate a successful return to remission. 5 The actual incidence of TP53 alterations in childhood ALL in Taiwan remains unknown. Therefore, we profiled the frequency of genetic alterations and impact of TP53 alterations on survival rate of relapsed childhood ALL patients treated with Taiwan Pediatric Oncology Group (TPOG) ALL protocols in a medical center in Taiwan.
| MATERIAL S AND ME THODS

| Patients and protocols
Bone marrow or peripheral blood samples taken at diagnosis, relapse, and/or clinical remission were available for 111 children with relapsed ALL; 98 with B-cell ALL, and 13 with T-cell ALL) from January 1997 to December 2015. These patients were enrolled in the TPOG ALL 93, ALL 97 very high risk (VHR), ALL 2002, or ALL 2013 protocols; details of these protocols have been published elsewhere. 15 The TPOG ALL 2013 was modified from ALL 2002 by incorporating minimal residual disease (MRD) measurements to stratify treatment. After disease relapse, physicians used different protocols, including the Berlin Frankfurt Münster (BFM) relapse protocol, upgrade to TPOG VHR protocols or FLAG. 5, 16, 17 This study was approved by the Institutional Review Board of National Taiwan University Hospital and all participants or their guardians provided written informed consent in accordance with the Declaration of Helsinki.
| Genomic DNA extraction
Lymphoblasts were purified from bone marrow or peripheral blood specimens by the Ficoll-Paque centrifugation method according to the manufacturer's instructions (GE Healthcare).
Genomic DNA was extracted from leukemic cells using standard phenol/chloroform-based methods. Briefly, 1 million cells were lysed in 10 mmol/L Tris-HCl, 10 mmol/L NaCl, 10 mmol/L EDTA, 20 μg proteinase K, and 0.5% SDS by incubating at 37°C for 16 hours. Total RNA was further removed by adding 500 μg PureLink RNase A (Invitrogen) and incubating for 10 minutes at 37°C. An equal volume of phenol-chloroform-isopropanol (25:24:1) was added to lysates and mixed by shaking vigorously, followed by centrifugation at 16 100 g at 4°C for 5 minutes. The upper aqueous phase was transferred to a fresh tube; genomic DNA was then precipitated by adding 2× volume −80°C 100% ethanol. The DNA pellet was washed with 75% ethanol and rehydrated with Tris-EDTA buffer. Concentration of DNA was determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). post-relapse. Patients with TP53 alterations (14/45) had inferior 5-year EFS and OS than patients without TP53 alterations after transplantation (P = .002 and P = .001, respectively). The significance of these TP53 alterations for patients who received transplantations was confirmed by multivariate analysis. In conclusion, TP53 alterations were enriched and useful as prognostic markers in relapsed childhood ALL. 
| Mutation analysis of TP53
| Multiplex ligation-dependent probe amplification
To detect structural alterations of TP53, multiplex ligation-de- 
| Statistical analyses
Equality between categoric and continuous parameters was tested with the chi-squared or Fisher's exact tests. 
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attributable to inadequate data. All tests were two-sided, and values of P < .05 were considered significant.
| RE SULTS
| Frequency and type of TP53 alterations in relapsed childhood ALL
Detailed clinical characteristics of the studied cohort are described in Table 1 . To obtain the associations of TP53 alterations with different clinical, cytogenetic, and treatment parameters present at the time of relapse, these variables between patients with or without TP53 alterations and between TP53 alteration subgroups were compared statistically ( Table 2 ). Hypodiploidy was enriched in TP53 alterations.
However, there were more patients with KMT2A rearrangements
and T-cell ALL in relapsed cases with TP53 alterations than patients with ETV6-RUNX1, hypodiploidy, and BCR-ABL1.
TP53 alterations were identified in 34 patients (31%). Within the B-cell ALL relapse group, 28 patients (29%) had TP53 gene alterations: six (21%) had deletions in the absence of a mutation (referred to as an "exclusive deletion"), 16 (57%) had mutation(s) in the absence of a deletion (referred to as an "exclusive mutation"), and six (21%) had mutation(s) and deletion(s). In T-cell ALL patients, TP53 alterations were identified in six patients (46%): three had an exclusive mutation, one had an exclusive deletion, and two had mutation(s) and a deletion ( Figure 1A) . TP53 P72R, a known polymorphism, exon 1 alterations, and intronic deletions were not evaluated in this study.
TP53 alterations are summarized in 
Analysis of patients with mutated vs deleted vs mutated and deleted vs wild-type TP53
Wild-type exclusive TP53 deletion. The most frequent TP53 mutations were detected in the DNA-binding domain (exons 5-8) ( Figure 1B) . In morphological remission samples, we identified missense mutations in two patients (478 and 508). There were eight patients with more than one TP53 alteration. There were six patients with multiple mutations, six with single mutations and single deletions, and two with single deletions and multiple mutations.
Alterationtype
P-value
| TP53 alterations in matched diagnosis and relapsed patients
Diagnostic and relapse samples were available for 69 patients.
Matched-initial ALL samples were compared with those from relapsed patients with TP53 alterations to trace whether TP53 alterations were persistent or acquired between initial diagnosis and first relapse. Approximately 70% of all mutations and deletions (16 of 24)
were relapse-specific ( Figure 1C ). One patient acquired an exclusive deletion, seven patients acquired an exclusive mutation, and three patients acquired both a mutation and a deletion at relapse. Five patients had relapse-specific mutations, but we lacked additional material to check for deletions of TP53. Seven patients had somatic mutations of the TP53 gene at first diagnosis. A single patient had both a mutation and a deletion at initial ALL diagnosis and acquired an additional mutation during relapse.
| Relationships between TP53 alterations and clinical characteristics and survival rate
Five-year EFS and OS were analyzed for patients with and without (Figure 4 ). Table 3 ).
| Multivariate analysis
Patients who received stem-cell transplantation presented with a better 5-year OS; however, this trend did not reach statistical significance.
In patients who received BMT, TP53 alterations (HR = 2.93; 95% CI: 1.46-5.87, P = .003) were identified as the strongest predictive factor for an unfavorable 5-year EFS. TP53 alterations (HR = 2.88; 95% CI: 1.37-6.07, P = .005) and age at onset of <1 year (HR = 3.05;
95% CI: 1.19-7.79, P = .02) were clinically significant (Table S2 ).
| D ISCUSS I ON
Approximately 31% of relapsed childhood ALL cases harbor genetic alterations of TP53, and the TP53-acquired alteration rate was 35% in sixty-nine patients with diagnostic samples to backtrack mutations, which is higher than that observed in Caucasian populations. Abbreviations: ALL, acute lymphoblastic leukemia; BMT, bone marrow transplantation; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival. Mutation type (reference = TP53 wild-type); Gender (reference = female); Age (reference = ≥1 y); ALL type (reference = T-ALL).
TA B L E 3
Five-year EFS and OS using univariate and multivariate survival analysis in relapsed pediatric ALL patients mutations in relapsed ALL patients in Taiwan. Given the much higher incidence of acquired TP53 alterations in childhood ALL, a larger clinical trial to detail the true somatic and germline variants of TP53 in other pediatric malignancies, particularly in relapsed samples, is worthy of investigation in Taiwan.
The prognostic values of TP53 alterations have been documented in several large-scale international clinical trials for relapsed childhood ALL. TP53 alterations are associated with nonresponse to chemotherapeutic treatment and poor EFS and OS. 10 Most groups used time to relapse, relapse site, and cytogenetic alterations to define risk groups after recurrence. 10 Patients with a TP53 alteration tended to have a very early relapse and should be classified and treated as high-risk patients. 11 Irrespective of the initial chemotherapy response, patients with TP53 alterations tend to have refractory disease, second relapses, and dismal outcomes. For relapsed T-cell ALL, TP53 mutations were the best predictor of a second event in the cohort of Richter-Pechańska. 18 Almost all patients with TP53 alterations died of disease very soon after relapse, whereas patients without TP53 alterations survived. In this cohort, 47 patients received BMT; infant ALL patients apparently did not benefit from stem-cell transplantation. Other treatment strategies might be indicated for this aggressive ALL. [22] [23] [24] Our analyses suggest that somatic alteration of TP53 at relapse is a good predictor of transplantation outcomes.
We identified two patients with TP53 mutations from remission samples, suggesting that these mutations were not somatic, but of germline origin. TP53 germline mutations are enriched in low-hypodiploidy patients and are common in Li-Fraumeni syndrome. 9 TP53 germline mutations result in a poorer outcome than other common subtypes of childhood ALL, such as ETV6-RUNX1 and hyperdiploidy.
A recent study showed TP53 germline variants (not common mutations) also contribute to significant clinical outcomes. 25 Excluding the low hypodiploidy subtype, which occurred in close relationship with TP53 germline mutations, children with TP53 pathogenic variants still experienced significantly worse outcomes than those without.
There have also been studies investigating the significance of 27 overall TP53 mutation incidence was 16%, increasing with age. In addition to the low hypodiploidy subtype, TP53 mutations were also enriched in ALL with MYC rearrangements, recently classified as a subtype of B-cell ALL. 28 Stengel et al used next-generation sequencing to profile the TP53 mutations.
In addition to low hypodiploidy, high TP53 mutation loads also correlated with high hyperdiploidy and complex karyotypes. B-cell ALL had a higher mutation load than T-cell ALL. Median OS was significantly shorter for patients with TP53 mutations than for patients with wild-type TP53. 27 Rebuilding tumor-suppressive functions by targeting mutant p53 proteins seems to be a reasonable therapeutic strategy and is likely worth future clinical trials. 29, 30 In conclusion, our findings indicate that TP53 alterations at relapse may be used as a molecular marker for therapeutic failure in 
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